Phase III
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
Bristol-Myers Squibb released data from pooled analyses of survival data from four clinical studies in patients with lung cancer treated with Opdivo (nivolumab).
Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
Bone marrow transplants are both incredibly risky as well as expensive procedures. Nonetheless, they are still effective and have been used by doctors since the 1950s, with many successful procedures completed over the years.
The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.
The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.
EMD Serono, a unit of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) had approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS).
During a presentation at the American Association for Cancer Research meeting over the weekend, Astellas touted new overall survival data for Xospata.
PRESS RELEASES